• UroGen published 2025 annual report highlighting FDA clearance and launch of Zusduri for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
• Early Zusduri launch tracked in line with internal expectations, supported by positive feedback from urologists and patients.
• Jelmyto maintained durable commercial base, supported by growing real-world evidence and continued adoption across practice settings.
• Pipeline focus shifted to next-generation mitomycin RTGel programs UGN-103 and UGN-104, with NDA filing for UGN-103 targeted for 2H 2026 and potential FDA decision in 2027.
• R&D portfolio expanded with UGN-501 oncolytic virus acquisition in February 2025, with Phase 1 start targeted by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.